Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
Certain portions of our press release dated May 9, 2017, a copy
of which is annexed hereto as Exhibit no. 99.1, are incorporated
by reference herein, and are filed to this Item 2.02. They are as
follows:
|
The 1st, 2nd, and 6th 8th paragraphs relating to results of operations for the first quarter of 2017 |
|
The 3rd full paragraph and portions of the 4th paragraph relating to results of European operations |
|
Portions of the 5th paragraph relating to results of United States operations |
|
The 9th paragraph relating to balance sheet items for the first quarter of 2017 |
|
The 12th paragraph relating to the conference call to be held on May 10, 2017 |
|
The consolidated statements of income and consolidated balance sheets |
Item 7.01 Regulation FD Disclosure
Certain portions of our press release dated May 9, 2017, a copy
of which is annexed hereto as Exhibit no. 99.1, are incorporated
by reference herein, and are filed to this Item 7.01 and
Regulation FD. They are as follows:
|
Portions of the 4th paragraph relating to new product launches for European operations for 2017 |
|
Portions of the 5th paragraph relating to new product launches for United States operations |
| The 10th paragraph relating to 2017 guidance |
|
The 14th paragraph relating to forward looking information |
|
The balance of such press release not otherwise incorporated by reference in Items 2.02 or 8.01 |
Item 8.01 Other Event.
Certain portions of our press release dated May 9, 2017, a copy
of which is annexed hereto as Exhibit no. 99.1, are incorporated
by reference herein, and are filed to this Item 8.01. They are as
follows:
| The 11th paragraph relating to cash dividends |
Item 9.01 Financial Statements and Exhibits
99.1 Our press release dated May 9, 2017
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. Inc. (NASDAQ:INCR) Recent Trading Information
Inc. (NASDAQ:INCR) closed its last trading session up +0.90 at 43.65 with 1,731,087 shares trading hands.
